HD-OPM Archive
Topics › Heart rhythm & heart failure

Hypertrophic cardiomyopathy affects 1 in 500 and is a top cause of athlete sudden death

Louis Nervegna · Apr 09, 2026 · ♥ 6 reactions · 3 comments · original Facebook post
Heart rhythm & heart failure
AI summary & key facts

Louis summarizes HCM, a genetic thickening of the left ventricle wall, often undiagnosed until symptoms. A Stanford item describes the path toward a heart disease drug; a linked article discusses rapamycin and feline HCM.

Hypertrophic cardiomyopathy (HCM) is a thickening of the heart muscle that is primarily caused by genetics.

It is not that common (1 in 500), and often goes undiagnosed until serious symptoms finally appear.

It is infamous for being the leading cause of sudden death in young athletes.

“People who have this condition, in which the heart beats too forcefully, experience a thickening of the interior wall of the heart’s left ventricle — the main pumping chamber that circulates oxygenated blood throughout the body. This thickening worsens over time, causing the heart to pump less effectively and may even block the flow of blood out of the heart.”

A drug called mavacamten has been a huge breakthrough in treating this disease, as first discovered at Stanford (based on 55 years of previous research at the university).

“Mavacamten has been the single largest therapeutic advance for this group of patients — really since ever,” said Victoria Parikh, MD, director of the Stanford Center for Inherited Cardiovascular Disease and an associate professor of medicine. “We’ve never had a precision therapy for hypertrophic cardiomyopathy until now, and patients often feel better almost immediately.”

Similar conditions (but less serious) can also be caused by:

See this previous post: ↪ HCM, athlete's heart and LVH look alike on imaging but differ greatly in risk.

It’s worth noting that this abnormal thickening of the heart muscle in HCM involves overactivation of the mTOR pathway. The drug rapamycin (an mTOR inhibitor) has also shown promise in treating hypertrophic cardiomyopathy. In fact, rapamycin (Felycin-CA1) is now conditionally-approved by the FDA to treat hypertrophic cardiomyopathy in cats, a species where the disease is much more common than humans: Broken hearts mended? Rapamycin shows promise preventing feline HCM pathology (AAHA). There are Facebook groups where people are using vet-prescribed rapamycin to treat their cats with HCM.

#cardiomyopathyHD #mavacamtenHD #stanfordHD #mtorHD #rapamycinHD #catsHD #hcmHD #lvhHD

One in 500 people have hypertrophic cardiomyopathy, a major cause of heart failure and the path to a heart disease drug shows the power of curiosity, collaboration and funding for open-ended scientific exploration to drive therapeutic discovery.

Stanford Medicine MagazineDrug discovery fueled by curiosity, teamwork and federal fundingThe path to a heart disease drug shows the power of curiosity, collaboration and funding for open-ended scientific exploration to drive therapeutic discovery.stanmed.stanford.eduNo photo description available.
← newer: Eric Verdin's five-tier evidence ranking for longevity supplolder: Higher CRP is more likely with obesity, smoking, female sex, →